What's New in Dry AMD Treatment? FDA-Approved Drugs to Know

New FDA-Approved Dry AMD Drugs

Dry age-related macular degeneration (AMD) affects the macula, the part of the retina responsible for central vision. In its advanced form, dry AMD can lead to geographic atrophy (GA), where retinal tissue gradually breaks down. For many years, management focused on nutritional supplements, smoking cessation, and monitoring. That changed when the FDA approved two drugs specifically for GA secondary to dry AMD. Syfovre (pegcetacoplan injection) received approval in February 2023, and Izervay (avacincaptad pegol intravitreal solution) was approved in August 2023. Both are given by intravitreal injection into the eye. They are not cures and do not restore lost vision; instead, they aim to slow the growth of GA lesions. Patients should discuss whether these treatments are appropriate for their stage of disease and overall eye health.

Syfovre vs. Izervay: How the New Treatments Compare

Syfovre and Izervay belong to a class called complement inhibitors. Syfovre targets complement protein C3, while Izervay targets C5. This difference matters for how the drugs work and how they are dosed. Syfovre is typically given every 25 to 60 days, depending on the treatment plan. Izervay is given monthly. Both require in-office injection and follow-up visits to check for complications. In clinical trials, both drugs slowed GA lesion growth over 12 months, but the effect size varied. Common side effects include eye discomfort, floaters, and temporary vision changes. More serious risks include endophthalmitis, retinal detachment, increased intraocular pressure, and conversion to wet AMD. Because these are new treatments, long-term data are still being collected. An eye care professional can help weigh the potential benefits against the risks for each patient.

Dry AMD Treatment Options: Benefits, Risks, and Costs

Dry AMD treatment options include FDA-approved injections, AREDS2 vitamin formulas, and lifestyle changes such as not smoking and managing blood pressure. AREDS2 supplements may slow progression in some people with intermediate AMD, but they are not a treatment for geographic atrophy. The new injections offer a way to target GA, yet they require ongoing appointments and may not work for everyone. Real-world cost is a major consideration. Medicare Part B often covers FDA-approved intravitreal injections when they are medically necessary, but patients may still owe coinsurance, deductibles, and administrative fees. Medicare Advantage and supplemental plans can change what a patient pays. Manufacturer assistance programs may also help eligible patients. Because coverage and pricing vary by plan and location, patients should contact their insurance provider and the drug manufacturer for current estimates before starting treatment.

Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Dry AMD is a complex condition, and the arrival of FDA-approved drugs has given patients and doctors more to consider. Syfovre and Izervay represent a shift toward treating geographic atrophy, but they are not right for everyone. Benefits, risks, and costs should be reviewed carefully with a retina specialist. Keeping up with regular eye exams remains important for monitoring changes and making timely decisions. As research continues, more data will clarify how these treatments perform over longer periods and how they fit into everyday care.